Development of influenza H7N9 virus like particle (VLP) vaccine: Homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus

Vaccine

Volumn 31, Issue 40, 2013, Pages 4305-4313

  Smith, Gale E ^a   Flyer, David C ^a   Raghunandan, Ramadevi ^a   Liu, Ye ^a   Wei, Ziping ^a   Wu, Yingyun ^a   Kpamegan, Eloi ^a   Courbron, Denise ^a   Fries, Louis F ^a   Glenn, Gregory M ^a  

^a NOVAVAX INC   (United States)

Author keywords

H7N9; Hemagglutinin; Influenza; Pandemic; Vaccine; Virus like particle

Indexed keywords

ANTIGEN; HEMAGGLUTININ; INFLUENZA H7N9 VIRUS LIKE PARTICLE VACCINE; INFLUENZA VACCINE; SIALIDASE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CROSS PROTECTION; CROSS REACTION; HEMAGGLUTINATION INHIBITION; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA A; INFLUENZA A (H7N9); INFLUENZA VIRUS A; INFLUENZA VIRUS A H7N3; INFLUENZA VIRUS A H7N9; INSECT CELL; LETHAL DOSE; LIMIT OF QUANTITATION; LUNG PARENCHYMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANDEMIC INFLUENZA; PRIORITY JOURNAL; SPODOPTERA FRUGIPERDA; SURVIVAL; VIRUS LIKE AGENT;

H7N9; HEMAGGLUTININ; INFLUENZA; PANDEMIC; VACCINE; VIRUS LIKE PARTICLE;

ANIMALS; ANTIBODIES, VIRAL; BACULOVIRIDAE; CELL LINE; CROSS PROTECTION; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININS, VIRAL; INFLUENZA A VIRUS, H7N3 SUBTYPE; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; SPODOPTERA; VACCINATION; VACCINES, SYNTHETIC; VIRAL MATRIX PROTEINS;

EID: 84882874443     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.07.043     Document Type: Article

References (22)

1. Schnirring L. Federal officials weigh H7N9 vaccine options. ; 2013 [accessed 13.06.13]. http://www.cidrap.umn.edu/cidrap/content/influenza/avianflu/news/jun1113vaccine.html.
2. Osterholm M.T., Ballering K.T., Kelley N.S. Major challenges in providing an effective and timely pandemic vaccine for influenza A(H7N9). JAMA 2013, 10.1001/jama.2013.6589.
3. Morens D.M., Taubenberger J.K., Fauci A.S. Pandemic influenza viruses - hoping for the road not taken. N Engl J Med 2013, 10.1056/NEJMp1307009.
4. Hu Y., Lu S., Song Z., Wang W., Hao P., Li J., et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 2013, 10.1016/S0140-6736(13)61125-3.
5. Dormitzer P.R., Suphaphiphat P., Gibson D.G., Wentworth D.E., Stockwell T.B., Algire M.A., et al. Synthetic generation of influenza vaccine viruses for rapid response to pandemics. Sci Transl Med 2013, 5:185ra68.
6. Cox M.M., Patriarca P.A., Treanor J. FluBlok, a recombinant hemagglutinin influenza vaccine. Influenza Other Respi Viruses 2008, 2:211-219.
7. De Groot A.S., Ardito M., Terry F., Levitz L., Ross T., Moise L., et al. Low immunogenicity predicted for emerging avian-origin H7N9. Hum Vaccin Immunother 2013, 9:1-7.
8. Lopez-Macias C., Ferat-Osorio E., Tenorio-Calvo A., Isibasi A., Talavera J., Arteaga-Ruiz O., et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded: randomized, placebo-controlled trial of adults in Mexico. Vaccine 2011, 29(44):7826-7834.
9. Khuran S., Wu J., Verma N., Verma S., Raghunandan R., Manischewitz J., et al. H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans. J Virol 2011, 85(21):10945-10954.
10. Pushko P., Tumpey T.M., Bu F., Knell J., Robinson R., Smith G., et al. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induced protective immune responses in BALB/c mice. Vaccine 2005, 23(50):5751-5759.
11. Bright R.A., Carter D.M., Crevar C.J., Toapanta F.R., Steckbeck J.D., Cole K.S., et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE 2008, 3(1):e1501.
12. WHO Disease Outbreak News Human Infection with Influenza A(H7N9) Virus in China - Update 2013, World Health Organization, Geneva. http://www.who.int/csr/don/en/index.html.
13. Gao R., Cao B., Hu Y., Feng Z., Wang D., Hu W., et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013, 368(20):1888-1897.
14. Couch R.B., Patel S.M., Wade-Bowers C.L., Nino D. A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine. PLoS ONE 2012, 7(12):e49704. 10.1371/journal.pone.0049704.
15. Cate R., Rayford Y., Nino D., Winokur P., Brady R., Belshe R., et al. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine 2010, 28:2076-2079.
16. ®-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly. Vaccine 2012, 30(7):1388-1396.
17. Leroux-Roels I., Borkowski A., Vanwolleghem T., Dramé M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomized controlled trial. Lancet 2007, 370(9587):580-589.
18. Skowronski D.M., Janjua N.Z., De Serres G., Hottes T.S., Dickinson J.A., Crowcroft N., et al. Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. BMJ 2011, 342:c7297.
19. Song H., Wittman V., Byers A., Tapia T., Zhou B., Warren W., et al. In vitro stimulation of human influenza-specific CD8+ T cells by dendritic cells pulsed with an influenza virus-like particle (VLP) vaccine. Vaccine 2010, 28(34):5524-5532.
20. Gravel C., Li C., Wang J., Hashem A.M., Jaentschke B., Xu K.W., et al. Qualitative and quantitative analyses of virtually all subtypes of influenza A and B viral neuraminidases using antibodies targeting the universally conserved sequences. Vaccine 2010, 28(36):5774-5784.
21. Kreijtz J.H., Osterhaus A.D., Rimmelzwaan G.F. Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control. Hum Vaccine 2009, 5(3):126-135.
22. (Identifier NCT01897701). http://www.clinicaltrials.gov/.